| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.09. | Jyong Biotech Ltd.: Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards | 2 | GlobeNewswire (USA) | ||
| 18.09. | Jyong Biotech Ltd.: Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei | 10 | GlobeNewswire (USA) | ||
| 16.09. | Jyong Biotech Ltd.: Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS-8 for Prostate Cancer Prevention | 282 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company", "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| 22.08. | Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP) | 4 | GlobeNewswire (USA) | ||
| JYONG BIOTECH Aktie jetzt für 0€ handeln | |||||
| 22.07. | Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention | 4 | GlobeNewswire (USA) | ||
| 18.06. | Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering | 3 | GlobeNewswire (USA) | ||
| 17.06. | Taiwan's Jyong Biotech doubles in value on Nasdaq debut | 2 | Investing.com | ||
| 17.06. | Jyong Biotech Ltd. IPO opens at $15 after pricing at $7.50 per share | 3 | Investing.com | ||
| 17.06. | Urinary disease biotech Jyong Biotech prices US IPO at $7.50, the low end of the range | 1 | Renaissance Capital | ||
| 17.06. | Jyong Biotech Prices 2.67M Share IPO at $7.50/sh | 2 | Investing.com | ||
| 17.06. | Jyong Biotech Announces Pricing Of 2.67 Mln Shares IPO At $7.50/Shr | 1 | RTTNews | ||
| 17.06. | Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering | 314 | GlobeNewswire (Europe) | New Taipei City, Taiwan, June 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (the "Company"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative... ► Artikel lesen | |
| 12.06. | Jyong Biotech Ltd. - 8-A12B, Registration of securities | - | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HELIX BIOPHARMA | 1,030 | -13,45 % | Helix Biopharma GAAP EPS of -$0.09 | ||
| GALECTO | 7,340 | -0,14 % | Galecto, Inc.: Galecto Reports Second Quarter 2025 Operating and Financial Results | BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced... ► Artikel lesen | |
| BIO-WORKS TECHNOLOGIES | 0,217 | -0,46 % | BIO-WORKS TECHNOLOGIES AB: Bio-Works forms strategic partnership with Zenmindes Biotechnology to strengthen presence in China | ||
| AVIDITY BIOSCIENCES | 69,80 | +0,17 % | Novartis kündigt die milliardenschwere Übernahme von Avidity Biosciences an, um damit das eigene Portfolio zu stärken | Bereits im Sommer wurde darüber gemunkelt, nun gibt es auch Gewissheit: Novartis übernimmt das US-Biotechunternehmen Avidity Biosciences und greift dafür tief in die Tasche. Zwölf Milliarden US-Dollar... ► Artikel lesen | |
| QIAGEN | 40,760 | +0,90 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,500 | -2,31 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| CABALETTA BIO | 3,625 | +47,66 % | Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials | ||
| EVOTEC | 7,054 | -0,59 % | BB Biotech & Evotec: Biotech immer noch historisch "billig"? Und die bessere Aktie ist? | BB Biotech & Evotec: Zwei Aktien, die ein klar unterschiedliches Risikopotential bieten. Deshalb die Frage: Wird höheres Risiko durch höhere Gewinnchncen ausgeglichen? Ein Aktienvergleich für Anleger... ► Artikel lesen | |
| BIONTECH | 90,40 | +0,22 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| RANI THERAPEUTICS | 2,185 | +52,80 % | Rani Therapeutics schließt Privatplatzierung ab und besetzt Vorstand neu | ||
| DYNE THERAPEUTICS | 22,580 | -4,08 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| BEAM THERAPEUTICS | 24,995 | +5,09 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 8,560 | +1,66 % | Morning Market Movers: Ventyx Biosciences, Brera Holdings, Safe & Green Holdings, American Rebel Holdings See Big Swings | CANBERA (dpa-AFX) - At 8:05 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| IMMUNOVANT | 24,700 | -0,44 % | Immunovant gains amid takeover speculation | ||
| INHIBRX BIOSCIENCES | 81,40 | +3,75 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |